middle.news
PYC Therapeutics Secures EMA Orphan Drug Designation for RP11 Candidate
10:14am on Monday 27th of April, 2026 AEST
•
Healthcare
Read Story
PYC Therapeutics Secures EMA Orphan Drug Designation for RP11 Candidate
10:14am on Monday 27th of April, 2026 AEST
Key Points
EMA grants Orphan Drug Designation to VP-001 for RP11
Designation offers 10 years market exclusivity and regulatory incentives
VP-001 holds multiple FDA special designations including Fast Track
Phase 2 trial ongoing with registrational study design pending
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
PYC Therapeutics (ASX:PYC)
OPEN ARTICLE